BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 22202581)

  • 1. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
    Hoshimoto S; Faries MB; Morton DL; Shingai T; Kuo C; Wang HJ; Elashoff R; Mozzillo N; Kelley MC; Thompson JF; Lee JE; Hoon DS
    Ann Surg; 2012 Feb; 255(2):357-62. PubMed ID: 22202581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
    J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.
    Hoshimoto S; Shingai T; Morton DL; Kuo C; Faries MB; Chong K; Elashoff D; Wang HJ; Elashoff RM; Hoon DS
    J Clin Oncol; 2012 Nov; 30(31):3819-26. PubMed ID: 23008288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
    Fusi A; Collette S; Busse A; Suciu S; Rietz A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
    Eur J Cancer; 2009 Dec; 45(18):3189-97. PubMed ID: 19793643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients.
    Koyanagi K; Kuo C; Nakagawa T; Mori T; Ueno H; Lorico AR; Wang HJ; Hseuh E; O'Day SJ; Hoon DS
    Clin Chem; 2005 Jun; 51(6):981-8. PubMed ID: 15817820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
    Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
    Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.
    Sotelo MJ; Sastre J; Maestro ML; Veganzones S; Viéitez JM; Alonso V; Grávalos C; Escudero P; Vera R; Aranda E; García-Alfonso P; Gallego-Plazas J; Lopez C; Pericay C; Arrivi A; Vicente P; Ballesteros P; Elez E; López-Ladrón A; Díaz-Rubio E
    Ann Oncol; 2015 Mar; 26(3):535-41. PubMed ID: 25515656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients.
    Nicholl MB; Elashoff D; Takeuchi H; Morton DL; Hoon DS
    Ann Surg; 2011 Jan; 253(1):116-22. PubMed ID: 21135695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Molecular Profiling of Circulating Tumor Cells from Patients with Melanoma Receiving Combinatorial Immunotherapy.
    Lin SY; Chang SC; Lam S; Irene Ramos R; Tran K; Ohe S; Salomon MP; Bhagat AAS; Teck Lim C; Fischer TD; Foshag LJ; Boley CL; O'Day SJ; Hoon DSB
    Clin Chem; 2020 Jan; 66(1):169-177. PubMed ID: 31672856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
    Faries MB; Mozzillo N; Kashani-Sabet M; Thompson JF; Kelley MC; DeConti RC; Lee JE; Huth JF; Wagner J; Dalgleish A; Pertschuk D; Nardo C; Stern S; Elashoff R; Gammon G; Morton DL;
    Ann Surg Oncol; 2017 Dec; 24(13):3991-4000. PubMed ID: 29019177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.
    Gogas H; Kefala G; Bafaloukos D; Frangia K; Polyzos A; Pectasides D; Tsoutsos D; Panagiotou P; Ioannovich J; Loukopoulos D
    Br J Cancer; 2002 Jul; 87(2):181-6. PubMed ID: 12107840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma.
    Brownbridge GG; Gold J; Edward M; MacKie RM
    Br J Dermatol; 2001 Feb; 144(2):279-87. PubMed ID: 11251559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients.
    Koyanagi K; Mori T; O'Day SJ; Martinez SR; Wang HJ; Hoon DS
    Cancer Res; 2006 Jun; 66(12):6111-7. PubMed ID: 16778184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.
    Kiyohara E; Hata K; Lam S; Hoon DS
    Methods Mol Biol; 2014; 1102():513-22. PubMed ID: 24258996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
    Morton DL; Hsueh EC; Essner R; Foshag LJ; O'Day SJ; Bilchik A; Gupta RK; Hoon DS; Ravindranath M; Nizze JA; Gammon G; Wanek LA; Wang HJ; Elashoff RM
    Ann Surg; 2002 Oct; 236(4):438-48; discussion 448-9. PubMed ID: 12368672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative RT-PCR assessment of melanoma cells in peripheral blood during immunotherapy for metastatic melanoma.
    Schmidt H; Sørensen BS; von der Maase H; Bang C; Agger R; Hokland M; Nexo E
    Melanoma Res; 2002 Dec; 12(6):585-92. PubMed ID: 12459648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course.
    Osella-Abate S; Quaglino P; Savoia P; Leporati C; Comessatti A; Bernengo MG
    Melanoma Res; 2002 Aug; 12(4):325-34. PubMed ID: 12170181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma.
    Mocellin S; Del Fiore P; Guarnieri L; Scalerta R; Foletto M; Chiarion V; Pilati P; Nitti D; Lise M; Rossi CR
    Int J Cancer; 2004 Sep; 111(5):741-5. PubMed ID: 15252844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.